Summary: A further 3 digoxin radioimmunoassay (RIA) kits have been evaluated for performance and cross-reaction with digitoxin, spironolactone, canrenone and furosemide (Lasix-Hoechst). Effects of serum protein concentrations have also been tested. The kits tested were from the following manufacturers:
Introduction
Following a recent publication (1) in which 6 digoxin kits were evaluated, one kit (Boehringer-Mannheim) has been retested with a different antibody, and a further 2 new kits have been included in this follow-up study.
Cross-reaction studies have been made with the most commonly occurring substances and metabolites that might be expected to interfere in the assay of serum digoxin. These were: spironolactone, canrenone, furosemide, digitoxin, serum albumin, | 8-and γ-globulins. These substances were tested in concentrations below, within and above the normal/therapeutic range. As a measure of the cross-reactivity, the "digoxin'Mevel was recorded at each concentration of the test-substance; this is a much better way of expressing the cross-reaction than the often used and somewhat misleading concept of displacement at 50% binding. 
Materials and Methods
The three kits tested were from the following manufacturers: A) Diagnostic Products Corporation Digoxin Kit (Biosigma GmbH, D-8000 M nchen 21) B) Byk-Mallinckrodt SPAC Digoxin Kit (Byk-Mallinckrodt GmbH, D-6057 Dietzenbach) C) Boehringer-Mannheim Digoxin Kit (Boehringer-Mannheim GmbH, D-8132 Tutzing). In all kits the antigen was labelled with 125 I. The Diagnostic Products Corporation (DPC) kit used a conventional double antibody separation, whereas the Byk-Mallinckrodt (SPAC) and Boehringer-Mannheim (B-M) kits both employed antibody-coated tubes. Tables 1 and 2 show the composition of the kits and the incubation schemes.
Digoxin, digitoxin, spironolactone and canrenone were from Boehringer-Mannheim, D-6800 Mannheim. Human serum albumin was bought from Sigma GmbH, D-8012 Neubiberg, and human β-and γ-globulins from Miles GmbH, D-6000 Frankfurt a. M.
Digoxin-free plasma for all studies was obtained from outdated blood-bank plasma.
All test substances, except the serum proteins, were made up in digoxin-free plasma.
Furosemide (Lasix-Hoechst, D-6000 Frankfurt a. M.) was used from the commercially available solution for intravenous application (10g/l).
Ringer solution (Fresenius) was made up according to DAB 7 and contained 147 mmol/1 Na*, 4.0 mmol/1 K*, 2.25 mmol/1 Ca 2+ , and 155 mmol/1 CP. Cross-reactivity studies Table 5 shows the reaction of the kits with digoxin and digitoxin in glycoside-free plasma. Table 6 shows the cross-reaction of spironolactone and canrenone in the kits. The cross-reaction is measured as "digoxin" measured at each point tested. This is the better way of showing the interference of spironolactone and canrenone, which can be present in serum at concentrations in excess of 1000 times those of digoxin, and where a percent cross-reactivity can appear deceptively low.
Results

Assay characteristics
The cross-reaction of digitoxin was lowest in the DPC kit and highest in the SPAC kit. The latter kit can be used to measure digitoxin in serum (see below). All kits measured digoxin within acceptable ranges when the kit standard curve was used as reference, although in the early SPAC kits, there was a considerable negative bias before the kit standards were changed for standards containing correct digoxin concentrations.
The cross-reactivity of spironolactone and canrenone were lowest in the B-M kit. In all kits, however, canrenone reacted with the antibody more than spironolactone. * The cross-reaction with furosemide was not detected in any of the 3 kits tested, even at a concentrations of Sg/lTab. 3. Standard curve reproducibility and sensitivity -mean and standard deviation. Effects of different serum-proteins on the maximum binding Table 7 shows the effects of albumin (1-20%) and | 3-and -globulins (1-5%) on the maximum binding. The proteins were dissolved in Ringer solution, so that only the protein under test was present in the tube. The 100% binding is the binding given by the zero standard in each kit. Both coated tube kits showed large differences in binding at different albumin concentrations; with the globulins, and with low concentrations of albumin, binding was well above 100%. The DPC kit, using conventional double antibody separation was affected little or not at all by the serum protein concentration. Table 9 shows the standards in the 3 kits as measured in the other 2 kits. For the SPAC kit the results in brackets were those from the earlier kits with the wrong concentrations above 1.28 nmol/1. the DPC kit measures the expected digoxin values in all kits. The coated tube kits showed some discrepancies. All standards showed a normal electrophöresis pattern \Vith a total serum protein of between 52 and 63 g/L.
Effects ofaldactone therapy on measured digoxin concentrations
Standards measured in all kits
Tab. 6. Cross-reactivity of Spironolactone and Canrenoneread off against kit standard curve. The measurement ofdigitoxin in serum with the SPAC kit Figure 1 shows the standard curves for digoxin and digitoxin in the SPAC digoxin kit. Both curves were set up using pure digoxin or digitoxin added to digitalisfree serum. The lowest detectable limit for digitoxin is around 1 nmol/1 with a 50% intercept of 14.4 nmol/1. The kit allows measurement ofdigitoxin up to 50 nmol/1 which covers both therapeutic and toxic levels. Table 10 shows the correlation of results in 67 patients undergoing digoxin therapy. The sera were measured in all kits in a single assay, the assays being carried out on the same day. All correlation coefficients are, as to be expected, highly significant but do not approach the ideal regression equation with a = 0 and b = .1 .
Correlation of results
Discussion
The cross-reaction of digoxin antisera with digitoxin can be used to advantage when it is large enough to allow a digitoxin standard curve to be plotted which covers the range of digitoxin found in patients under- levels of digitoxin in serum as found by Smith (2) were 22 ± 10 nmol/1 for non-toxic cases, and 44 ± 8 nmol/1 for toxic cases.
The cross-reaction of digoxin antisera with digitoxin is not linear throughout the concentration range as seen in table 5, and it is often confusing to read in kit instructions that for example, the cross-reaction of the kit antisera to digitoxin is 10%. The SPAC-kit allows measurement of digitoxin in serum as seen in figure 1 . As a practical example, a patient was admitted to the emergency ward, unconscious and suspected of having digitalis overdose. The preparation was unknown. With the SPAC-kit the patient serum gave a "digoxin" level of 3.42 nmol/1 and a "digitoxin" level of 38 nmol/1. The DPC-kit gave a "digoxin" level of 0.28 nmol/1. Both SPAC values were in the toxic range whereas that from the DPC-kit was under the therapeutic range. The digitalis preparation was later confirmed to be Digimerck, a digitoxin preparation. The SPAC-kit gave useful information in this case arid the DPC-kit would have registered no case of intoxication due to its low cross-reactivity to digitoxin!
The coated tube kits gave problems with abnormally serum protein concentrations which could be a hindrance in the case of serum from dialysis patients and others with dysproteinaemia. Effects of serum proteins and renal insufficiency have been described in part for both 12S I-and 3 H-methods (3-7). It has been known for some time that simultaneous Spironolactone (Aldactone) treatment and digoxin therapy Values are the means from at least 3 assays in which each standard was run in duplicate.
often give rise to toxic serum digoxin levels, even though no symptoms of an overdose are evident. Spironolactone has a similar structure to digoxin and has a digoxin antagonist effect (8) . It also cross-reacts with some digoxin antisera which can cause havoc, since Spironolactone may be present in serum at concentrations above 1000 times that of digoxin. Spironolactone is rapidly metabolised in the body to several metabolites with differing biological and immunological properties (9) . At least 9 metabolites have been classified (9) of which canrenone and canrenoic acid are the main ones (9-10).
The affinity of canrenone for the digoxin antisera was higher than that shown by Spironolactone for the anti-•sera tested here, although the concentrations of canrenone in serum are usually much lower than those for Spironolactone. Assuming a complete distribution in the blood, the maximum Spironolactone levels after a 200 mg i/v dose with a blood volume of 5 liters would be 40 mg/1. The maximum canrenone levels in serum are obtained about 2 h after administration of Spironolactone. After a single dose of 200 mg Spironolactone, the maximal canrenone concentration observed by Karim and co-workers was 0.40 mg/1 (9 " often seen in digitalis intoxication patients. Bearing these facts in mind, care must be used when interpreting results from patients on either spironolactone or canrenoate therapy.
There was no cross-reaction of the three antibodies to furosemide, which is probably to be expected as this molecule shows no spatial similarities to digoxin.
The coefficients of variation, both intra-and interassay, were greater in the coated tube kits, as already shown previously (1) . The stability of the standard curves in serial assays is good, but not good enough for a short-cut suggested by Boehringer-Mannheim in their kit instructions. Here, it is stated that the standard curve tubes used in one assay can be stored and used in subsequent assays over the next 14 days, provided that the quality-control serum, supplied in the kit, and run with each assay, gives results from this standard curve which lie within the prescribed limits. This is a false economy step which contravenes all accepted quality-control concepts.
The instructions contained in each kit gave detailed information on carrying out the test, and in the case of the DPC and SPAC kits, also the clinical relevance of the test. The DPC-kit in its original form had more useful data on recovery experiments and inter-and intra-assay variation.
The SPAC-kit contained one mistake in the French and English versions, that of the cross-reaction of the antibody with j8-acetyl digoxin at 40%, whereas in the German edition it is given, correctly, at 90%.
To conclude, this study has shown that of the 3 kits tested none is ideal for all situations, a finding which repeats those of an earlier investigation (1).
